CN119110806A - 新型抗fgfr2抗体 - Google Patents

新型抗fgfr2抗体 Download PDF

Info

Publication number
CN119110806A
CN119110806A CN202380031311.1A CN202380031311A CN119110806A CN 119110806 A CN119110806 A CN 119110806A CN 202380031311 A CN202380031311 A CN 202380031311A CN 119110806 A CN119110806 A CN 119110806A
Authority
CN
China
Prior art keywords
antibody
antigen
binding fragment
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380031311.1A
Other languages
English (en)
Chinese (zh)
Inventor
周添添
杜庆林
韩淑华
彭菲
杨雪艳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Original Assignee
Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd filed Critical Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Publication of CN119110806A publication Critical patent/CN119110806A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202380031311.1A 2022-03-28 2023-03-28 新型抗fgfr2抗体 Pending CN119110806A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/083269 2022-03-28
CN2022083269 2022-03-28
PCT/CN2023/084213 WO2023185778A1 (en) 2022-03-28 2023-03-28 Novel anti-fgfr2 antibodies

Publications (1)

Publication Number Publication Date
CN119110806A true CN119110806A (zh) 2024-12-10

Family

ID=88199423

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380031311.1A Pending CN119110806A (zh) 2022-03-28 2023-03-28 新型抗fgfr2抗体

Country Status (9)

Country Link
EP (1) EP4499701A4 (https=)
JP (1) JP2025513745A (https=)
KR (1) KR20250042203A (https=)
CN (1) CN119110806A (https=)
AU (1) AU2023243773A1 (https=)
CA (1) CA3246949A1 (https=)
IL (1) IL315970A (https=)
MX (1) MX2024011805A (https=)
WO (1) WO2023185778A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118772279A (zh) * 2024-06-28 2024-10-15 北京普利米特生物科技有限公司 抗FGFR2b抗体或其抗原结合片段及其用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202600596A (zh) * 2024-03-04 2026-01-01 大陸商杭州中美華東製藥有限公司 抗ＦＧＦＲ２ｂ抗體、其抗體藥物偶聯物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089193A1 (en) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
PH12021552742A1 (en) * 2013-08-01 2022-05-23 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
KR20220019839A (ko) * 2013-10-08 2022-02-17 다이이찌 산쿄 가부시키가이샤 항 fgfr2 항체와 타제의 조합
EP3287522A4 (en) * 2015-04-20 2019-03-27 Daiichi Sankyo Company, Limited DETECTION OF FGFR2
US20220010020A1 (en) * 2018-10-05 2022-01-13 Five Prime Therapeutics, Inc. Anti-FGFR2 Antibody Formulations
CA3160810A1 (en) * 2019-12-24 2021-07-01 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
MX2022007961A (es) * 2019-12-24 2022-07-12 Dizal Jiangsu Pharmaceutical Co Ltd Nuevos anticuerpos anti-fgfr2b.
US20230052256A1 (en) * 2019-12-24 2023-02-16 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118772279A (zh) * 2024-06-28 2024-10-15 北京普利米特生物科技有限公司 抗FGFR2b抗体或其抗原结合片段及其用途
CN118772279B (zh) * 2024-06-28 2025-03-25 北京普利米特生物科技有限公司 抗FGFR2b抗体或其抗原结合片段及其用途

Also Published As

Publication number Publication date
MX2024011805A (es) 2024-11-08
CA3246949A1 (en) 2023-10-05
WO2023185778A1 (en) 2023-10-05
EP4499701A4 (en) 2026-02-25
IL315970A (en) 2024-11-01
WO2023185778A9 (en) 2023-11-02
JP2025513745A (ja) 2025-04-30
KR20250042203A (ko) 2025-03-26
EP4499701A1 (en) 2025-02-05
AU2023243773A1 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
KR102156199B1 (ko) 항-cd73 항체 및 이것의 사용
CN114040926B (zh) 结合cd123的多肽及其用途
AU2007315211B2 (en) FGFR4 antibodies
KR101809072B1 (ko) 항-cxcr4 항체 및 항체-약물 접합체
KR102084806B1 (ko) 인테그린 αvβ6에 대한 항체 및 암을 치료하기 위한 그의 용도
JP2021510141A (ja) Ｉｇおよびｉｔｉｍドメインを持つｔ細胞免疫受容体（ｔｉｇｉｔ）に対する抗体およびその使用
JP2020180135A (ja) 抗ｐｄ−ｌ１抗体およびその使用
JP6113933B1 (ja) 繊維芽細胞増殖因子受容体３（ｆｇｆｒ３）に対する化合物および治療的使用
KR102608723B1 (ko) 항―ｐｄ－１ 항체 및 그의 용도
CN114040927A (zh) 结合cd33的多肽及其用途
JP2021512613A (ja) 二重特異性抗原結合分子及びその使用方法
CN119110806A (zh) 新型抗fgfr2抗体
KR20160072268A (ko) 항-efna4 항체-약물 접합체
WO2024199362A1 (en) Novel anti-FGFR2 antibodies
EP4624492A1 (en) Anti-ccr8 antibody and use thereof
JP2026504499A (ja) 抗ｃｄ１６ａ抗体およびその使用
CN120958025A (zh) 针对含cub结构域的蛋白1(cdcp1)的抗体及其用途
KR20230154981A (ko) 항-인간 cxcr5 항체 및 이의 용도
CN117355331A (zh) 抗Siglec组合物及其用途
WO2021032130A1 (zh) Bcma抗体
HK40114936A (zh) 新型抗fgfr2抗体
EA052794B1 (ru) Новые антитела против fgfr2
CN121152808A (zh) 抗ccr8抗体和抗ccr8/ctla4双特异性抗体
CN116323658A (zh) 靶向PD-1或PD-L1和TGF-β的双功能蛋白及其医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40114936

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination